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i:10.1016/j.rmedc.2008.10.016Profuse lung bleeding caused by tumoral infiltration,
a sudden clinically challenging emergent state, can cause
life-threatening hypoxemia and hemodynamic instability.1
Ankaferd blood stopper (ABS) is a unique standardized
medicinal plant extract, which has been approved in the
management of post-surgery external bleeding and dental
surgery in Turkey.2 ABS induces a very rapid formation (less
than 1 s) of a specific hemostatic protein network within
vital erythroid aggregation in the injured vascular area.2
Data on the efficacy of ABS for the management of bleedings
of difficult clinical states are limited to case reports only.3e5
We, herein, present a non-small cell lung cancer patient
presenting with severe hemoptysis leading to hypoxemia
and hemodynamic instability, which had successfully been
controlled via the endoscopic application of ABS.123051543.
ail.com (I.C. Haznedaroglu).
ll rights reserved.A 62-year-old man was admitted into the emergency
room because of severe hemoptysis, hypoxemia, anemia
and hemodynamic instability. Emergent fiberoptic bron-
choscopy revealed that the right intermediate bronchus
orifice was almost completely occluded by an actively
bleeding endobronchial neoplastic lesion (Fig. 1A). Subse-
quent tissue biopsies were taken from the lesion and 2 ml of
ABS was administered topically to the bleeding mass
because of the emergent life-threatening state, and
hemostasis was achieved within seconds (Fig. 1B). No sign
of bleeding was observed in the following days. The patient
was hemodynamically stabilized. Histopathological
appearance of the tissues after Ankaferd application is
correlated to reveal that ABS does result in the formation of
unique erythroid-rich aggregates within the eosinophilic
protein network (Figs. 2 and 3). Furthermore, poor-differ-
entiated squamous cell carcinoma cells were trapped
within the ABS-induced hemostatic network (Fig. 4).
Figure 1 Fiberoptic bronchoscopy revealed that the right
intermediate bronchus orifice was almost completely occluded
by a bleeding neoplastic endobronchial lesion (A). Subsequent
tissue biopsies were taken from the lesion and 2 ml of ABS was
administered topically to the bleeding mass, and hemostasis
was achieved within seconds (B).
Figure 2 Erythroid aggregates within the fibrinoid material
and eosinophilic mass protein network induced by Ankaferd
blood stopper (Hþ E 40).
Figure 3 Eosinophilic mass protein network covering groups
of induced erythroid aggregates by Ankaferd blood stopper
(Hþ E 1000).
Figure 4 Poor-differentiated squamous cell carcinoma cells
trapped within the Ankaferd-induced hemostatic network
(Hþ E 200).
Endobronchial application of ankaferd blood stopper 145Lung bleedings may represent a real diagnostic and
therapeutic challenge as in our patient. Effective
management of the bleeding problem is particularly
required in patients with hereditary and acquired hemor-
rhagic diathesis including neoplasia and the use of antico-
agulant, antihemostatic drugs.6 ABS, a standardized
mixture of five plants, provides immediate hemostasis.
A study showed that its effect is not dependent on individual
coagulation factors and platelets.2 Its hemostatic success in
primary and secondary hemostatic defects has been sup-
ported with in vivo and in vitro observations.2e5 Neither any
local adverse effect nor systemic toxicity was observed
following the bronchoscopic application of ABS. Therefore,
physiological cell-based coagulation could be clinically
managed via topical Ankaferd application to prevent and
treat bleeding in many distinct clinicopathological states.
146 S. Arslan et al.Since there is a close correlation between tumor growth
and hemostasis of cancer,7,8 the effect of ABS among other
hemostatic agents9 should also be further searched.
Controlled clinical studies should be performed regarding
the efficacy of ABS in the controlling of emergency
bleedings.
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